Skip to main content
. 2016 Sep 16;31(6):1361–1364. doi: 10.1007/s11011-016-9910-2

Table 2.

Beneficial effects of non-absorbable disaccharides on serious adverse events in randomized clinical trials

Serious adverse events RR (95 % CI) Trials (n) Patients (n)
Liver failure 0.35 (0.11–1.15) 4 241
Spontaneous bacterial peritonitis 0.86 (0.32–2.30) 2 278
Variceal haemorrhage 0.46 (0.28–0.98) 9 681
Hepatorenal syndrome 0.47 (0.21–1.04) 3 278
Overall 0.47 (0.36–0.60) 24 1487

(adapted from Gluud et al. 2016)